Pfizer Inc. lost an appeal in a U.K. patent dispute over Lyrica, which generated sales of $4.8 billion last year. According to a Bloomberg article, three London judges upheld a 2015 ruling that Allergan’s Actavis unit didn’t infringe Pfizer patents with its drug pregabalin. Teva bought that business this year.
Pfizer has also sued Dr. Reddy’s Laboratories and Teva Pharmaceutical Industries Ltd. over their generic pregabalin products.
Read the Bloomberg story